Program: SOHO 2021

If you have already registered for SOHO 2021, we suggest that you test your access to the virtual event platform at https://soho.click/ve. Select "System Check" under the "Login" button to ensure that your internet connection and computer are compatible with the system. The virtual environment will open on Sunday, September 5th at 5:00 PM CDT to allow users to test login and navigation. To login, enter the email address that you used to register for the meeting. No Password is required for login purposes. Your registration in the SOHO 2021 registration system is linked to the SOHO 2021 virtual event platform.

The Society of Hematologic Oncology's Ninth Annual Meeting is scheduled as a virtual event on September 8-11, 2021. The focus of the 3.5-day program is cutting-edge approaches in the field of hematologic malignancies. The meeting includes a variety of educational formats including: general sessions, meet-the-professor sessions, breakfast with the expert, debates, case presentations, plenary sessions and a number of informal events.

Below you will find the SOHO 2021 Program-at-a-Glance and detailed program. Note that SOHO members have early access to session selections. To sign-up for FREE SOHO membership, go to the SOHO membership site.

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
6:00 AM	E-POSTER SESSION I
MEET-THE-PROFESSOR SESSION I
6:45 AM	MTP Session I: AML
	Session Chair: Lucy Godley
	Familial Predisposition to AML: How Far Are We in the Understanding?	Lucy A. Godley, MD, PhD	The University of Chicago Medicine, Chicago, Illinois, USA
	Beyond BCL2 Inhibition: Prospects for MCL1 Inhibitors and Others	Marina Konopleva, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Single Cell Profiling in AML	Koichi Takahashi, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6:45 AM	MTP Session II: ALL
	Session Chair: Wendy Stock
	Approach to the Elderly Patient with ALL	Sabina Chiaretti, MD, PhD	Sapienza University, Rome, Italy
	Novel Transplant and Post-Transplant Options in ALL	Aaron Logan, MD, PhD	UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
	Use of BCL2 Inhibitors in ALL	Wendy Stock, MD	The University of Chicago Medicine, Chicago, Illinois, USA
6:45 AM	MTP Session III: NHL
	Session Chair: Mark Roschewski
	Primary CNS Lymphoma	Lakshmi Nayak, MD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
	Prophylaxis and Management of Secondary CNS Lymphoma	Mark J. Roschewski, MD	National Cancer Institute, Bethesda, Maryland, USA
	Prognostication and Treatment of Burkitt Lymphoma in the Modern Era	Adam J. Olszewski, MD	Alpert Medical School of Brown University, Providence, Rhode Island, USA
6:45 AM	MTP Session IV: NHL
	Session Chair: Philippe Armand
	Relapsed/Refractory T-cell Lymphoma	Pierluigi Porcu, MD	Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
	Hodgkin Lymphoma: What to Do When Checkpoint Inhibitors Fail	Philippe Armand, MD, PhD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
	POD24 in Follicular Lymphoma: What Time has Taught Us	Nathan H. Fowler, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6:45 AM	MTP Session V: CML
	Session Chair: Jerald Radich
	Response and Progression in CML	Jerald P. Radich, MD	University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
	Importance of BCR-ABL Transcript Type in CML	Nick Cross, MA, PhD, FRCPath	University of Southampton, Salisbury, United Kingdom
	New Drugs, New Challenges in CML	Jorge Cortés, MD	Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
6:45 AM	MTP Session VI: MPN
	Session Chair: Andreas Reiter
	Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Diagnosis	Annette S. Kim, MD, PhD, FCAP	Brigham and Women’s Hospital, Boston, Massachusetts, USA
	Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment	Andreas Reiter, MD	University Medical Center Mannheim, Mannheim, Germany
	Chronic Eosinophilic Leukemia: Diagnosis and Therapy	Jason R. Gotlib, MD, MS	Stanford University, Stanford, California, USA
6:45 AM	MTP Session VII: MDS
	Session Chair: Guillermo Montalban-Bravo
	A Primer on the Biology of MDS	Simona Colla, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Update on CMML	Guillermo Montalban-Bravo, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Update on Clonal Hematopoiesis	Kelly Bolton, MD, PhD	Washington University School of Medicine, St. Louis, Missouri, USA
6:45 AM	MTP Session VIII: MM
	Session Chair: Sagar Lonial
	Other Plasma Cell Disorders
	Novel Agents for Waldenstrom's Macroglobulinemia	Jorge J. Castillo, MD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
	How to Recognize and Treat MGRS	Nelson Leung, MD	Mayo Clinic Rochester, Rochester, Minnesota, USA
	Bone Disease in MM	Matthew T. Drake, MD, PhD	Mayo Clinic Rochester, Rochester, Minnesota, USA
6:45 AM	MTP Session IX: CLL
	Session Chair: William Wierda
	Case Studies in CLL
	2 Case studies CLL	Nicole Lamanna, MD	Columbia University and at New York Presbyterian Hospital, New York, New York, USA
	2 Case studies CLL	John M. Burke, MD	US Oncology, Aurora, Colorado, USA
	2 Case studies CLL	Deborah M. Stephens, DO	The University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, USA
6:45 AM	MTP Session X: CT
	Session Chair: Saul Priceman
	Cellular Therapies for Solid Tumors
	TILS for Melanoma	Omid Hamid, MD	Cedars-Sinai, The Angeles Clinic and Research Institute, Los Angeles, California, USA
	CARS for Solid Tumors	Roisin E. O'Cearbhaill, MD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
	CARS for Prostate Cancer	Saul Priceman, PhD	City of Hope National Medical Center, Duarte, California, USA
7:45 AM	BREAK
MEET-THE-PROFESSOR SESSION II
8:00 AM	MTP Session XI: AML
	Session Chair: Tapan Kadia
	How Can We Improve on MRD Assessment by Flow Cytometry	Sylvie Freeman, DPhil, MBChB, MRCP, FRCPath	The University of Birmingham, Birmingham, United Kingdom
	Menin Inhibitors in AML, What are the Prospects?	Eunice Wang, MD	Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
	Novel Strategies to Treat Elderly with AML	Tapan M. Kadia, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM	MTP Session XII: ALL
	Session Chair: Partow Kebriaei
	Chemotherapy Free Regimens in ALL	Matthew Wieduwilt, MD, PHD	OU Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
	Approach to Philadelphia Chromosome Positive ALL	Partow Kebriaei, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Chemoresistance and Drug Profiling in ALL	Beat C. Bornhauser, PhD	University Children’s Hospital Zurich, Zurich, Switzerland
8:00 AM	MTP Session XIII: NHL
	Session Chair: Jorge J. Castillo
	Tailoring Therapy in Waldenstrom Macroglobulinemia	Jorge J. Castillo, MD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
	New Agents in Marginal Zone Lymphoma	Pier Luigi Zinzani, MD, PhD	University of Bologna, Bologna, Italy
	Case Discussion in Rarer Subtypes of Indolent B-Cell Lymphoma	Izidore Lossos, MD	University of Miami, Miami, Florida, USA
8:00 AM	MTP Session XIV:NHL
	Session Chair: Jeremy Abramson
	Update on CD19-Directed CAR T-Cell Therapy in B-Cell Lymphoma	Federick Locke, MD	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
	Novel Cellular Therapies in Development for Lymphoma	Barbara Savoldo, MD, PhD	University of North Carolina Health, Chapel Hill, North Carolina, USA
	Managing B-Cell Lymphoma Post CAR T-Cell Therapy	Jeremy S. Abramson, MD	Massachusetts General Hospital, Boston, Massachusetts, USA
8:00 AM	MTP Session XV: CML
	Session Chair: Jerald Radich
	Genomically Guided Therapy in CML	Timothy P. Hughes, MD, FRACP, FRCPA	South Australian Health and Medical Research Institute, Adelaide, Australia
	Blast Crisis CML	Michael Deininger, MD, PhD	Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA
	Molecular Testing of CML Patients in 2021: Between Old and New Tools	Simona Soverini, MD	University of Bologna, Bologna, Italy
8:00 AM	MTP Session XVI: MPN
	Session Chair: Andreas Reiter
	Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Diagnosis	Annette S. Kim, MD, PhD, FCAP	Brigham and Women’s Hospital, Boston, Massachusetts, USA
	Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment	Andreas Reiter, MD	University Medical Center Mannheim, Mannheim, Germany
	Chronic Eosinophilic Leukemia: Diagnosis and Therapy	Jason R. Gotlib, MD, MS	Stanford University, Stanford, California, USA
8:00 AM	MTP Session XVII: MDS
	Session Chair: Rami Komrokji
	Treatment of Lower Risk MDS	Rami Komrokji, MD	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
	How Do I Treat: Higher Risk MDS	Andrew Brunner, MD	Massachusetts General Hospital, Boston, Massachusetts, USA
	Use of Oral Hypomethylating Agents in MDS	Guillermo Garcia-Manero, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM	MTP Session XVIII: MM
	Session Chair: Suzanne Lentzsch
	Non-BCMA Immunotherapy in MM
	Next Generation CD38 Antibodies and Antibodies with Novel Targets GPRC5D and FcRH5	Thomas G. Martin, MD	University of California San Francisco, San Francisco, California, USA
	Next Generation Cellular Therapies: NK Cells, AlloCARs, Vaccines, etc.	Nina Shah, MD	University of California San Francisco, San Francisco, California, USA
	Infection in the CD38 and Anti-BCMA Era: Prevention and Treatment	Noopur Raje, MD	Massachusetts General Hospital, Boston, Massachusetts, USA
8:00 AM	MTP Session XIX: CLL
	Session Chair: Jennifer Woyach
	Relapsed and Refractory CLL
	Resistance to BCL-2i	Constantine S. Tam, MBBS, MD	Peter MacCallum Cancer Centre, Victoria, Australia
	Resistance to BTKi	Jennifer A. Woyach, MD	Ohio State University, Columbus, Ohio, USA
	Cell Based Therapy	Thomas Kipps, MD, PhD	University of California, San Diego, California, USA
8:00 AM	MTP Session XX: CT
	Session Chair: Marcela Maus
	Late Toxicities of Cellular Therapies
	Chronic GVHD - New Therapies	Daniel R. Couriel, MD, MS	University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, USA
	CAR Induced Cytopenia	Tania Jain, MBBS, MD	John Hopkins University, Baltimore, MD, USA
	Long Term Follow up of CAR T Recipient	Marcela V. Maus,MD, PhD	Massachusetts General Hospital, Boston, Massachusetts, USA
9:00 AM	BREAK
TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA
Session Chairs: Lori Muffly and Ching-Hon Pui
9:15 AM	Welcome and Opening Remarks	Susan O'Brien	President, Society of Hematologic Oncology
9:25 AM	Hyper CVAD in 2021: Lessons Learned and New Approaches	Elias Jabbour, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:40 AM	Q & A
9:43 AM	Measurable Residual Disease in Acute Lymphoblastic Leukemia: Optimization and Innovation in 2021 and Beyond	Lori Muffly, MD	The University of Stanford, Stanford, California, USA
9:58 AM	Q & A
10:01 AM	Novel CAR-T Constructs for ALL	Peggy Peihua Lu, MD, PhD	Hebei Yanda Lu Daopei Hospital, Hebei, China
10:16 AM	Q & A
10:19 AM	Asparaginase: Understanding and Overcoming Toxicities	Ibrahim T. Aldoss, MD	City of Hope Comprehensive Cancer Center, Duarte, California, USA
10:34 AM	Q & A
10:37 AM	Novel approaches to T-Cell ALL	David T. Teachey, MD	Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
10:52 AM	Q & A
10:55 AM	DEBATE: Optimal Time for Blinatumomab: Is it Time for MRD?	Rachel Rau, MD	Baylor College of Medicine, Houston, Texas, USA
11:10 AM	DEBATE: Optimal Time for CAR-T: Is it Time for MRD?	Rebecca A. Gardner, MD	Seattle Children's Hospital, Seattle, Washington, USA
11:25 AM	Q & A
11:31 AM	Oral Abstract - ALL-031: The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia	Shawn Lee, MD	St. Jude Children's Research Hospital, Memphis, Tennessee, USA
INDUSTRY EXPERT SESSION I
11:41 AM	Continued Treatment in AML: The Role of Onureg (azacitidine) tablets
	Farhad Ravandi-Kashani, MD \| MD Anderson Cancer Center \| Houston, TX, USA
	This activity is sponsored by Bristol Myers Squibb
INDUSTRY EXPERT SESSION II
11:41 AM	ZYNLONTA™, the First-and-Only CD19-Targeted ADC, for the Treatment of Adults with R/R DLBCL After Two or More Lines of Systemic Therapy
	Adolfo Enrique Diaz Duque, MD, MSc \| UT Health San Antonio, Mays Cancer Center, San Antonio, Texas, USA
	This activity is sponsored by ADC Therapeutics
12:41 PM	BREAK
PLENARY SESSION I
Session Chair: Susan O'Brien
1:11 PM	Keynote Speaker: Managing Patients Relapsed or Refractory to Targeted Therapy	Jennifer R. Brown, MD, PhD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA

SESSION II: MYELODYSPLASTIC SYNDROMES
Session Chairs: Guillermo Garcia-Manero and David Sallman
1:31 PM	New Approaches for Lower Risk MDS	Uwe Platzbecker, MD	Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany
1:46 PM	Q & A
1:49 PM	New Immunotherapy Approaches for MDS	Uma Borate, MD, MS	Ohio State University James Cancer Hospital, Columbus, Ohio, USA
2:04 PM	Q & A
2:07 PM	NED Inhibition	Lionel Adès, MD, PhD	Hôpital Saint-Louis, Paris, France
2:22 PM	Q & A
2:25 PM	BCL-2 Inhibition in MDS	Andrew Wei, MBBS, PhD	Alfred Hospital and Monash University, Melbourne, Australia
2:40 PM	Q & A
2:43 PM	Targeting p53 in MDS	David A. Sallman, MD	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
2:58 PM	Q & A
3:01 PM	Oral Abstract - MDS-229 Assessment of Baseline Clinical and Molecular Characteristics in Indolent Chronic Myelomonocytic Leukemia	Luis E. Aguirre, MD	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
3:11 PM	BREAK
SESSION III: ACUTE MYELOID LEUKEMIA
Session Chairs: Farhad Ravandi
3:31 PM	IDH Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy	Courtney D. DiNardo, MD, MSCE	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
3:46 PM	Q & A
3:49 PM	NPM1 Mutated AML: From Bench to Bedside	Brunangelo Falini, MD	University of Perugia, Perugia, Italy
4:04 PM	Q & A
4:07 PM	FLT3 mutated AML: Moving Towards Cure	Alexander E. Perl, MD	University of Pennsylvania, Philadelphia, Pennsylvania, USA
4:22 PM	Q & A
4:25 PM	Antibody-Based Therapy in AML: Immunotoxins and Bi-specifics	Amir Fathi, MD	Massachusetts General Hospital, Boston, Massachusetts, USA
4:40 PM	Q & A
4:43 PM	TP53 Mutated AML: New Horizons	Naval Daver, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
4:58 PM	Q & A
5:01 PM	DEBATE: Is Maintenance Therapy in AML Necessary? YES	Farhad Ravandi, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
5:16 PM	DEBATE: Is Maintenance Therapy in AML Necessary? NO	Jeffrey E. Lancet, MD	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
5:31 PM	Q & A
5:37 PM	Measurable Residual Disease in AML	Jacqueline Cloos, PhD	Amsterdam UMC, Amsterdam, The Netherlands
5:52 PM	Q & A
5:55 PM	Oral Abstract - AML-024 Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia	Curtis Lachowiez, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6:05 PM	Oral Abstract - AML-345: Algorithmic Diagnostic Approach and Spectrum of Hematological Malignancies in Patients with Germline Predisposition Syndromes	Alejandro Ferrer, PhD	Mayo Clinic Rochester, Rochester, Minnesota, USA
6:15 PM	ADJOURN
POSTER SESSION & WELCOME RECEPTION (Non-Accredited)
6:15 PM	POSTER AWARDS
6:30 PM	E-POSTER SESSION II
INDEPENDENT SATELLITE SYMPOSIUM II
7:30 PM	Exploring New Approaches for Treating Patients with Cytopenic Myelofibrosis
	John Mascarenhas, MD \| Icahn School of Medicine at Mount Sinai, New York, New York, USA Prithviraj Bose, MD \| The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Bart L. Scott, MD \| Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
	This CME activity is provided by Medscape. This activity is supported by an educational grant from CTI BioPharma Corp. For more information and to register for this ISS, go to www.medscape.org/symposium/mf-cytopenic
INDEPENDENT SATELLITE SYMPOSIUM III
7:30 PM	Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes
	Moderator: Neil Love, MD \| Research To Practice \| Miami, Florida, USA Daniel A Pollyea, MD, MS \| University of Colorado School of Medicine \| Aurora, Colorado, USA David Sallman, MD \| Moffitt Cancer Center \| Tampa, Florida, USA Eunice S Wang, MD \| Roswell Park Comprehensive Cancer Center \| Buffalo, New York, USA Courtney D DiNardo, MD, MSCE \| The University of Texas MD Anderson Cancer Center \| Houston, Texas, USA
	This CME activity is provided by Research To Practice. This activity is supported by educational grants from Abbvie Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo, Genentech, a member of the Roche Group, Gilead Sciences Inc and Jazz Pharmaceuticals Inc. For more information and to register for this ISS, go to http://www.researchtopractice.com/Meetings/ISS-SOHO2021/AML-MDS.

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM IV
6:15 AM	Seizing the Day’ with BTK Inhibitors in CLL
	Co-Chair and Moderator, Nicole Lamanna, MD \| Herbert Irving Comprehensive Cancer Center, New York, New York, USA Co-Chair and Presenter, Jennifer Woyach, MD \| The Ohio State University, Columbus, Ohio, USA
	This educational live symposium is accredited by Medical Learning Institute, Inc. for CME/MOC. This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education. This activity is supported by an independent educational grant from AstraZeneca. To register for this live web broadcast, go to PeerView.com/CLL-Virtual2021
BREAKFAST WITH THE EXPERT I
6:45 AM	How I Use MRD: European and American Perspectives	Othman Al-Sawaf, MD	University Hospital of Cologne, Cologne, Germany
		Matthew S. Davids, MD, MMSc	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
7:45 AM	BREAK
SESSION IV: MYELOPROLIFERATIVE NEOPLASMS
Session Chairs: Olatoyosi Odenike and Jason Gotlib
8:00 AM	Simple Guideline to Systemic Mastocytosis in 2021	Jason R. Gotlib, MD, MS	Stanford University, Stanford, California, USA
8:15 AM	Q & A
8:18 AM	Polycythemia Vera: Is it Time to Rethink Treatment?	Francesco Passamonti, MD	University of Insubria, Varese, Italy
8:33 AM	Q & A
8:36 AM	Evolution in Prognostication in Myelofibrosis: From IPSS and DIPSS to MIPSS-70 and MYSEC-PM	Laura C. Michaelis, MD	Medical College of Wisconsin, Milwaukee, Wisconsin, USA
8:51 AM	Q & A
8:54 AM	Accelerated Phase of MPN: What Is It and What to Do About It	Olatoyosi Sobulo Odenike, MD	The University of Chicago Medicine, Chicago, Illinois, USA
9:09 AM	Q & A
9:12 AM	Potential New Therapeutic Approaches for Myelofibrosis	Srdan Verstovsek, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:27 AM	Q & A
9:30 AM	Oral Abstract- MPN-133 : Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the REVEAL Prospective, Observational Study	Carole B. Miller, MD	Ascension Saint Agnes Hospital, Baltimore, Maryland, USA
9:40 AM	BREAK
SESSION V: CHRONIC LYMPHOCYTIC LEUKEMIA
Session Chairs: Alessandra Ferrajoli and Jennifer Brown
10:10 AM	Molecular and Microenvironmental Basis of Immunodysfunction in CLL	Silvia Deaglio, MD, PhD	University of Turin, Turin, Italy
10:25 AM	Q & A
10:28 AM	Spectrum/Management of Infections in Patients with CLL	Carsten U. Niemann, MD, PhD	Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
10:43 AM	Q & A
10:46 AM	DEBATE: Old Prognostic Markers Still Have a Role in CLL Management	Inhye Ahn, MD	National Institutes of Health Clinical Center, Bethesda, Maryland, USA
11:01 AM	DEBATE: Old Prognostic Markers Have No Role in CLL Management	Steven Coutre, MD	Stanford University School of Medicine, Stanford, California, USA
11:16 AM	Q & A
11:22 AM	Approaches to Therapy of Richter Syndrome	Davide Rossi, MD, PhD	Institute of Southern Switzerland, Bellinzona, Switzerland
11:37 AM	Q & A
11:40 AM	New Targetable Pathways	Alexey V. Danilov, MD, PhD	City of Hope National Medical Center, Duarte, California, USA
11:55 AM	Q & A
11:58 AM	Oral Abstract - CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study	Catherine C. Coombs, MD	The University of North Carolina Cancer Center, Chapel Hill, North Carolina, USA
INDUSTRY EXPERT SESSION III (Non-Accredited)
12:08 PM	Clinical Cases in Polycythemia Vera: When to Intervene With Jakafi® (rollatini) \| Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea
	David Rizzieri, MD \| The Novant Health Cancer Institute \| Durham, North Carolina, USA
	This activity is sponsored by Incyte
INDUSTRY EXPERT SESSION IV (Non-Accredited)
12:08 PM	Discover the Role of Two Immunotherapies in Myeloma Treatment
	William Velasquez, MD \| Memorial Hermann \| Houston, Texas, USA
	This activity is sponsored by Bristol Myers Squibb
PLENARY SESSION II
Session Chair: Hagop Kantarjian
1:38 PM	How I Treat PV Before and After Fibrotic Transformation	Ayalew Tefferi, MD	Mayo Clinic Rochester, Rochester, Minnesota, USA
Recipient of the SOHO 2021 Distinguished Lecturer Award
SESSION VI: CHRONIC MYELOID LEUKEMIA
Session Chairs: Jorge Cortés and Ehab Atallah
1:58 PM	State of the Art in CML: Update	Andreas Hochhaus, MD	University Medical Center Jena, Jena, Germany
2:13 PM	Q & A
2:16 PM	CML and Pregnancy	Elisabetta Abruzzese, MD, PhD	S.Eugenio University Hospital, Rome, Italy
2:31 PM	Q & A
2:34 PM	Update on TFR	Ehab L. Atallah, MD	Medical College of Wisconsin, Milwaukee, Wisconsin, USA
2:49 PM	Q & A
2:52 PM	Managing TKI Resistance: New Options	Delphine Rea, MD, PhD	Hôpital Saint Louis, Paris, France
3:07 PM	Q & A
3:10 PM	Case Study: Managing Cytopenias on TKI Therapy	Jane F. Apperley, MBChB, MD, FRCP, FRCPath	Hammersmith Hospital London Imperial College, London, United Kingdom
3:25 PM	Q & A
3:28 PM	Oral Abstract – CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)	Jorge Cortés, MD	Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
3:28 PM	BREAK
SESSION VII: MULTIPLE MYELOMA
Session Chairs: Sagar Lonial and Suzanne Lentzsch
4:08 PM	Frontline Therapy for Amylodosis: Response Assessments	Angela Dispenzieri, MD	Mayo Clinic Rochester, Rochester, Minnesota, USA
4:23 PM	Q & A
4:26 PM	Salvage Therapy for Amyloidosis: Agents and Anti-Fibril Therapy	Suzanne Lentzsch, MD, PhD	Columbia University and at New York Presbyterian Hospital, New York, USA
4:41 PM	Q & A
4:44 PM	Frontline Therapy in TE NDMM: Pros and Con's; Quads, Early Transplant, Just Revlimid for Maintenance?	Amrita Y. Krishnan, MD, FACP	City of Hope National Medical Center, Duarte, California, USA
4:59 PM	Q & A
5:02 PM	Sequencing Treatment for Early Relapse: Which Triplets and When?	Maria-Victoria Mateos, MD, PhD	University Hospital of Salamanca, Spain
5:17 PM	Q & A
5:20 PM	Treatment of Triple Class Refractory Myeloma: Novel Agents	Robert Z. Orlowski, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
5:35PM	Q & A
5:38 PM	Novel BCMA Targeted ADCs, Bispecific and Trispecific Antibodies	Saad Z. Usmani, MD, FACP	Levine Cancer Institute, Charlotte, North Carolina, USA
5:53 PM	Q & A
5:56 PM	BCMA Directed CAR T-Cells: Early Results and Future Directions	Jesus G. Berdeja, MD	Sarah Cannon Cancer Institute, Nashville, Tennessee, USA
6:11 PM	Q & A
6:14 PM	Oral Abstract - MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)	Saad Z. Usmani, MD, FACP	Levine Cancer Institute, Charlotte, North Carolina, USA
6:24PM	ADJOURN
INDUSTRY EXPERT SESSION V (Non-Accredited)
6:24 PM	A Case-based Presentation on Improving Outcomes in Patients With Newly-Diagnosed Secondary AML
	James McCloskey, MD \| Chief of Leukemia, John Theurer Cancer Center \| Hackensack University Medical Center, Hackensack, NJ
	This activity is sponsored by Jazz Pharmaceuticals
INDUSTRY EXPERT SESSION VI (Non-Accredited)
6:24PM	Considerations for Tailoring Treatment for First-Line and Relapsed/Refractory Follicular Lymphoma
	TBD
	This activity is sponsored by Genentech
INDEPENDENT SATELLITE SYMPOSIUM V
7:24 PM	Personalizing Care for Patients with Low- to High-Risk MDS: Applying the Science to Real-World Case Scenarios
	Chair: Guillermo Garcia-Manero, MD \| The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Kelly S. Chien, MD \| The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Rami S. Komrokji, MD \| H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
	This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by an educational grant from Bristol Myers Squibb. For more information and to register for this ISS, go to https://www.gotoper.com/go/soho2021mds-wc.
INDEPENDENT SATELLITE SYMPOSIUM VI
7:24 PM	Medical Crossfire®: How Are We Meeting the Needs of Patients With CLL Across Lines of Care?
	Chair: William G. Wierda, MD, PhD , The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Faculty: Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, New York, USA Faculty: Nitin Jain, MD, , The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Genentech, Lilly and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc. For more information and to register for this ISS, go to https://www.gotoper.com/go/soho2021cll-wc.

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM VII
6:15 AM	Regimen Choice and Newly Approved Agents in Relapsed/Refractory Multiple Myeloma
	Chair: Sagar Lonial, MD, FACP \| Winship Cancer Institute of Emory University \| Atlanta, Georgia, USA Faculty: Tom Martin, MD \| University of California San Francisco \| San Francisco, California, USA Krina Patel, MD, MSc \| UT MD Anderson Cancer Center \| Houston, Texas, USA
	This CME activity is jointly provided by the University of Nebraska Medical Center and Bio Ascend. This activity is supported by an educational grant from Bristol Myers Squibb and Oncopeptides, Inc. For more information and to register for this ISS, go to https://bioascend.com/featured-activities/sohomm2021/
INDEPENDENT SATELLITE SYMPOSIUM VII A
6:30 AM	Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics
	Co-Chair & Moderator, Srdan Verstovsek, MD, PhD \| The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Co-Chair & Presenter, Ruben A. Mesa, MD, FACP \| Mays Cancer Center at UT Health San Antonio MD Anderson \| San Antonio, Texas, USA
	This educational live symposium is accredited by Medical Learning Institute, Inc. for CME/MOC. This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education. This activity is supported through educational grants from Bristol Myers Squibb, Constellation Pharmaceuticals, and Incyte Corporation. To register for this live web broadcast, go to PeerView.com/MF-Virtual2021
7:45 AM	BREAK
SESSION VIII: HODGKIN LYMPHOMA
Session Chairs: Ann Lacasce
8:00 AM	Integrating Novel Agents into the Treatment of Classic Hodgkin Lymphoma	Ann Lacasce, MD, MMSc	Dana Farber Cancer Institute, Boston, Massachusetts, USA
8:15 AM	Q & A
8:18 AM	Treatment Strategies in Nodular Lymphocyte Predominant Hodgkin Lymphoma	Ranjana H. Advani, MD	Stanford University Medical Center, Stanford, California, USA
8:33 AM	Q & A
SESSION IX: T-CELL LYMPHOMA
Session Chairs: Mary Jo Lechowicz and Ryan Wilcox
8:36 AM	New Pathways and New Targets in PTCL	Ryan A. Wilcox, MD, PhD	University of Michigan, Ann Arbor, Michigan, USA
8:51 AM	Q & A
8:54 AM	Moving Beyond BV-CHP in PTCL	Neha Mehta-Shah, MD	Washington University School of Medicine, St. Louis, Missouri, USA
9:09 AM	Q & A
9:12 AM	Treatment of Advanced CTCL in 2021	Lauren C. Pinter-Brown, MD	UCI Health, Chao Family Comprehensive Cancer Center, Orange, California, USA
9:27 AM	Q & A
9:30 AM	Immunotherapy Approaches in T-Cell Lymphoma	Maksim Mamonkin, PhD	Baylor College of Medicine, Houston, Texas, USA
9:45 AM	Q & A
9:48 AM	Disparities in Treatment in Patients with T-Cell Lymphoma	Mary Jo Lechowicz, MD	Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
10:03 AM	Q & A
10:06 AM	Oral Abstract: TCL-150 The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma	Swaminathan P. Iyer, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
10:16 AM	BREAK
SESSION X: INDOLENT B-CELL LYMPHOMA
Session Chairs: Nathan Fowler and Christopher Flowers
10:46 AM	Molecular Pathogenesis of Follicular Lymphoma and Its Relevance to Clinical Practice	Jessica Okosun, MA, MB BChir, MRCP, FRCPath, PhD	Barts Cancer Institute, London, United Kingdom
11:01 AM	Q & A
11:04 AM	Sequencing Therapy in Follicular Lymphoma	Peter Martin, MD	Weill Medical College of Cornell University, New York, New York, USA
11:19 AM	Q & A
11:22 AM	Novel Therapies in Indolent Lymphoma	Loretta Nastoupil, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
11:37 AM	Q & A
11:40 AM	Car T-Cell Therapy in Indolent Lymphoma	Caron A. Jacobson, MD, MMSc	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
11:55 PM	Q & A
11:58 PM	Oral Abstract - IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia	Jithma Abeykoon, MD	Mayo Clinic Rochester, Rochester, Minnesota, USA
INDUSTRY EXPERT SESSION VII (Non-Accredited)
12:08 PM	Treatment for CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma) and Waldenstroms Macroglobulinemia (WM)
	Moshe Y. Levy, MD \| Baylor University Medical Center, Houston, Texas, USA
	This activity is sponsored by Janssen Biotech & Pharmacyclics, LLC
INDUSTRY EXPERT SESSION VIII (Non-Accredited)
12:08 PM	A Treatment Option for Patients with Myelodysplastic Syndromes
	Thomas William LeBlanc, MD \| Duke University School of Medicine \| Durham, North Carolina, USA
	This activity is sponsored by Bristol Myers Squibb
1:08 PM	BREAK
PLENARY SESSION III
Session Chair: Sagar Lonial, MD, FACP
1:38 PM	From Biology to Therapy: Progress in Hodgkin Lymphoma	Stephen M. Ansell, MD, PhD	Mayo Clinic Rochester, Rochester, Minnesota, USA
SESSION XI: AGGRESSIVE B-CELL LYMPHOMA
Session Chairs: Laurie Sehn and Gilles Salles
1:58 PM	Dissecting the Biology of DLBCL: How Close Are We to a Clinically Validated Molecular Platform?	Georg Lenz, MD	University Hospital Münster, Münster, Germany
2:13 PM	Q & A
2:16 PM	Innovative Approaches in Untreated DLBCL	Jason R. Westin, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2:31 PM	Q & A
2:34 PM	Sequencing Therapies in Transplant-Ineligible DLBCL	Laurie H. Sehn, MD, MPH	BC Cancer, Vancouver, Canada
2:49 PM	Q & A
2:52 PM	The Next Wave of Novel Agents in Aggressive B-Cell Lymphoma	Gilles Salles, MD, PhD	Memorial Sloan Kettering Cancer Center, New York, New York, USA
3:07 PM	Q & A
3:10 PM	Update on Primary Mediastinal B-Cell Lymphoma	Kieron M. Dunleavy, MD	Georgetown University, Washington DC, USA
3:25 PM	Q & A
3:28 PM	High Grade B-Cell Lymphoma : Double/Triple Hit and NOS	Andrew Davies, MD	University of Southampton, Southampton, United Kingdom
3:43 PM	Q & A
3:46 PM	Oral Abstract - ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Brad S. Kahl, MD	Washington University Medical School, St. Louis, Missouri, USA
3:56 PM	Oral Abstract - ABCL-360:Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (Pts)	Cyrus Khan, MD	Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, USA
4:06 PM	BREAK
SESSION XII: MANTLE CELL LYMPHOMA
Session Chairs: Thomas Witzig and Michael Wang
4:36 PM	Dissecting the Biology of Mantle Cell Lymphoma: What is Clinically Relevant	Thomas Witzig, MD	Mayo Clinic Rochester, Rochester, Minnesota, USA
4:51 PM	Q & A
4:54 PM	Tailoring Upfront Therapy in Mantle Cell Lymphoma	Brad S. Kahl, MD	Washington University Medical School, St. Louis, Missouri, USA
5:09 PM	Q & A
5:12 PM	Novel Treatment Approaches in Relapsed/Refractory MCL	Kami J. Maddocks, MD	Ohio State University, James Comprehensive Cancer Center, Columbus, Ohio, USA
5:27 PM	Q & A
5:30 PM	CAR T-Cell Therapy in Mantle Cell Lymphoma	Michael Wang, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
5:45 PM	Q & A
5:48 PM	ADJOURN
INDUSTRY EXPERT SESSION IX (Non-Accredited)
5:48 PM	Monjuvi (Tafasitamab-cxix) For Use As Second-Line Therapy in Adult Patients with R/R DLBCL, in Combination with Lenalidomide
	Ruemu E. Birhiray, MD \| Hematology-Oncology of Indiana, Indianapolis, Indiana, USA
	This activity is sponsored by Incyte and MorphoSys
INDUSTRY EXPERT SESSION X (Non-Accredited)
6:48 PM	POLIVY+BR: Advance the Possibilities in R/R DLBCL, NOS, After at Least 2 Prior Therapies
	John R. Pawloski, MD, PHD \| Program Director, Cellular Therapy \| Tampa General Hospital, Tampa, Florida, USA
	This activity is sponsored by Genentech
INDEPENDENT SATELLITE SYMPOSIUM VIII
7:48 PM	Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA
	Sagar Lonial, MD \| Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA Thomas G. Martin, MD \| University of California San Francisco, San Francisco, California, USA Suzanne Lentzsch, MD, PhD \| Columbia University and at New York Presbyterian Hospital, New York, USA
	This CME activity is provided by Clinical Care Options, LLC. This activity is supported by an educational grant from GlaxoSmithKline.
INDEPENDENT SATELLITE SYMPOSIUM IX
7:48 PM	Medical Crossfire®: How Are We Integrating New Treatment Strategies into the Care of Our B-Cell Lymphoma Patients?
	Philippe Armand, MD, PhD \| Dana-Farber Cancer Institute \| Boston, Massachusetts, USA Loretta J. Nastoupil, MD \| The University of Texas MD Anderson Cancer Center \| Houston, Texas, USA Chair: Jason Westin, MD, MS, FACP \| The University of Texas MD Anderson Cancer Center Houston, Texas, USA
	This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Genmab USA, Inc., Incyte Corporation, Janssen Biotech, Inc., Pharmacyclics, an AbbVie Company and TG Therapeutics, Inc.

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
INDUSTRY SATELLITE SESSION X
6:15 AM	CAR T Cell Therapy in Lymphoma and Myeloma in Clinical Practice
	Christopher Flowers, MD \| UT MD Anderson Cancer Center \| Houston, Texas, USA Loretta Nastoupil, MD \| UT MD Anderson Cancer Center \| Houston, Texas, USA Noopur Raje, MD \| Dana-Farber Cancer Institute \| Boston, Massachusetts, USA
	This activity is supported by independent educational grants from Bristol-Myers Squibb and Legend Biotech USA Inc. For more information and to register for this ISS, go to https://bioascend.rievent.com/a/RCOMAF
BREAKFAST WITH THE EXPERT III
6:45 AM	Cell Therapy for Myeloma: When, Where, and What Type	Sergio Giralt, MD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
7:45 AM	BREAK
SESSION XIII: CELLULAR THERAPY
Session Chairs: Eric Smith and Adam Schoenfeld
8:00 AM	Microbiome and CAR T Cells	Melody Smith, MD, MS	Stanford University, Stanford, California, USA
8:15 AM	Q & A
8:18 AM	Cytotoxic T Lymphocyte Therapy for Viral Infection	Amanda L. Olson, MD	The University of Texas at MD Anderson Cancer Center, Houston, Texas, USA
8:33 AM	Q & A
8:36 AM	NYESO Targeted TCRs	Adam J. Schoenfeld, MD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
8:51 AM	Q & A
8:54 AM	CAR T for Pediatric ALL: What's Next?	Stephan Grupp, MD, PhD	University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA
9:09 AM	Q & A
9:12 AM	Oral Abstract: CT-080 A Tumor-Agnostic TCR-Mimic CAR-T cell Specific for NDC80 Targets Multiple Hematological Malignancies	Martin G. Klatt, MD	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
9:22 AM	BREAK
SESSION XIV: NEXT QUESTIONS
Session Chairs: Susan O'Brien and Hagop Kantarjian
9:52 AM	Next Questions: Acute Lymphoblastic Leukemia	Bijal Shah MD	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
10:02 AM	Next Questions: Acute Myeloid Leukemia	Hagop Kantarjian, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
10:12 AM	Next Questions: Cellular Therapy	Marcela V. Maus, MD, PhD	Massachusetts General Hospital, Boston, Massachusetts, USA
10:22 AM	Next Questions: Chronic Lymphocytic Leukemia	Susan O'Brien, MD	UCI Health Chao Family Comprehensive Cancer Center, Orange, California, USA
10:32 AM	Next Questions: Chronic Myeloid Leukemia	Jorge Cortés, MD	Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
10:42 AM	Next Questions: Aggressive B-Cell Lymphoma	Grzegorz S. Nowakowski, MD	Mayo Clinic Rochester, Rochester, Minnesota, USA
10:52 AM	Next Questions: Indolent B-Cell Lymphoma	Judith Trotman, MBChB, FRACP, FRCPA	Concord Repatriation General Hospital, Sydney, Australia
11:02 AM	Next Questions: T-Cell Lymphoma	Barbara Pro, MD	Robert H Lurie Cancer Center, Northwestern University-Feinberg School of Medicine, Chicago, Illinois, USA
11:12 AM	Next Questions: Mantle Cell Lymphoma	Martin Dreyling, MD, PhD	University of Munich, Munich, Germany
11:22 AM	Next Questions: Hodgkin Lymphoma	Craig H. Moskowitz, MD	University of Miami Health System, Miami, Florida, USA
11:32 AM	Next Questions: Multiple Myeloma	Ola C. Landgren, MD, PhD	University of Miami Health System, Miami, Florida, USA
11:42 PM	Next Questions: Myelodysplastic Syndromes	Guillermo Garcia-Manero, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
11:52 PM	Next Questions: Myeloproliferative Neoplasms	Srdan Verstovsek, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:02 PM	CLOSING REMARKS/ GAME WINNERS	Susan O'Brien, MD	President, Society of Hematologic Oncology
12:12 PM	ADJOURN

	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
ON-DEMAND INDEPENDENT EXPERT SESSION I (Non-Accredited)
	BLENREP belantamab mafodotin-blmf for injection 100mg
	Rafat Abonour, MD, Indianapolis, IN
	This activity is sponsored by GlaxoSmithKline
ON-DEMAND INDEPENDENT EXPERT SESSION II (Non-Accredited)
	BLENREP REMS: Real World Implementation and Best Practices
	Cristina Gasparetto, MD, Associate Professor of Medicine, Durham, North Carolina, USA Mark Newman, OD, MS, Optix Eyecare Center, Durham, North Carolina, USA
	This activity is sponsored by GlaxoSmithKline
ON-DEMAND INDEPENDENT EXPERT SESSION III (Non-Accredited)
	AYVAKIT: The ONLY Targeted Therapy for Advanced Systemic Mastocytosis Designed for Potent and Selective Inhibition of KIT D816V
	Andrew Kuykendall, MD \| H. Lee Moffitt Cancer Center, Tampa, Florida, USA
	This activity is sponsored by Blueprint Medicines Corporation
ON-DEMAND INDUSTRY SATELLITE SYMPOSIA I
	Navigating Treatment Options for CML Across the Disease Continuum: An Expert Case- Based Discussion
	Chair: Elias Jabbour \| MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Faculty: Hagop M. Kantarjian, MD \| The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Faculty: Shilpa Paul, PharmD, BCO \| The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by an educational grant from Novartis. For more information and to register for this ISS, go to https://www.gotoper.com/go/soho21cml

ON-DEMAND INDUSTRY SATELLITE SYMPOSIA II
	Advances in MF and PV: Individualizing Care Based on Patient- and Disease-Specific Factors
	Chair: Srdan Verstovsek, MD, PhD \| The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Faculty: Andrew Kuykendall, MD \| Moffitt Cancer Center, Tampa, Florida, USA Faculty: Raajit K. Rampal, MD, PhD \| Memorial Sloan Kettering Cancer Center, New York, New York, Faculty: Abdulraheem Yacoub, MD \| The University of Kansas Medical Center, Kansas City, Kansas, USA
	This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Bristol Myers Squibb, Incyte Corporation, Protagonist Therapeutics, SDP Oncology. For more information and to register for this ISS, go to https://www.gotoper.com/go/soho21mpn
ON-DEMAND INDUSTRY SATELLITE SYMPOSIA III
	Managing Multiple Myeloma from Newly Diagnosed to Relapsed/Refractory Settings: An Expert Case-Based Discussion
	Chair: Saad Z. Usmani, MD, MBA, FACP \| Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA Faculty: Surbhi Sidana, MD \| Stanford University, Stanford, California, USA Faculty: Carlyn R. Tan, MD, Memorial Sloan Kettering Cancer Center, New York, New York, USA
	This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Sanofi Genzyme, Karyopharm Therapeutics, Oncopeptides. For more information and to register for this ISS, go to https://www.gotoper.com/go/soho21mm
ON-DEMAND INDUSTRY SATELLITE SYMPOSIA IV
	How Can We Be More Strategic in Treatment Planning for Patients with ALL?
	Chair: Elias Jabbour, MD \| The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Faculty: Jae H. Park, MD \| Memorial Sloan Kettering Cancer Center, New York, New York, USA Faculty: Jerald P. Radich, MD \| Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
	This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from Amgen, Inc and Takeda Oncology.

ON-DEMAND INDUSTRY SATELLITE SYMPOSIA V
	Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Patients with Chronic Lymphocytic Leukemia
	Faculty: Jeff Sharman, MD \| Willamette Valley Cancer Institute and Research Center \| Eugene, Oregon, USA Faculty: Mitchell R Smith, MD, PhD \| GW Cancer Center \| Washington, DC, USA Faculty: Philip A Thompson, MB, BS \| The University of Texas MD Anderson Cancer Center \| Houston, Texas, USA Moderator: Neil Love, MD \| Research To Practice \| Miami, Florida, USA
	This CME activity is provided by Research To Practice. This activity is supported by an educational grant from Bristol Myers Squibb

ON-DEMAND INDUSTRY SATELLITE SYMPOSIA VI
	Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Patients with Non-Hodgkin Lymphoma
	Faculty: Andrew M Evens, DO, MSc \| Rutgers Biomedical and Health Sciences, Rutgers University \| New Brunswick, New Jersey, USA Faculty: Ian W Flinn, MD, PhD \| Sarah Cannon Research Institute \| Nashville, Tennessee, USA Faculty: Gilles Salles, MD, PhD \| Memorial Sloan Kettering Cancer Center \| New York, New York, USA Moderator: Neil Love, MD \| Research To Practice \| Miami, Florida, USA
	This CME activity is provided by Research To Practice. This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Incyte Corporation, Lilly, Novartis and TG Therapeutics Inc.

MEETING PROGRAM

SOHO 2021 Program

Program-at-a-Glance

Detailed Program

About the Society of Hematologic Oncology